Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MACROGENICS INC

Get SEC filing alerts via email and in your feed for MACROGENICS INC

MGNX

MACROGENICS INC

About MACROGENICS INC

MacroGenics, Inc. is a biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of innovative antibody-based cancer therapeutics. Its core platforms include bispecific and multi-specific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. The company targets solid tumors and hematologic malignancies, leveraging proprietary technologies and strategic collaborations to advance its pipeline and generate revenue through licensing, partnerships, and manufacturing services.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from MACROGENICS INC

1
1
MACROGENICS INC MacroGenics Reports $20.8M Revenue in Q1 2026, Driven by Contract Manufacturing and Royalty Increases

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
MACROGENICS INC MacroGenics Reports $149.5 Million Revenue for Fiscal Year 2025, Net Loss Increases to $74.6 Million

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
MACROGENICS INC MacroGenics Reports $72.8 Million Revenue in Q3 2025, Down 34% Year-Over-Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
MACROGENICS INC MacroGenics Reports 106% Revenue Growth to $22.2 Million, Net Loss Improves

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
MACROGENICS INC MacroGenics Reports 45% Revenue Growth to $13.2 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
MACROGENICS INC MacroGenics Reports 156% Revenue Growth to $150M in 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
MACROGENICS INC MacroGenics Reports Significant Revenue Growth, Net Income Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments